Mark Hsieh
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, DNA and Nucleic Acid Chemistry, Protein purification and stability, Bacterial Genetics and Biotechnology, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Predicting Antibody Developability Profiles Through Early Stage Discovery Screening(2020)207 cited
- → Comparison of the DNA Association Kinetics of the Lac Repressor Tetramer, Its Dimeric Mutant LacI , and the Native Dimeric Gal Repressor(1997)48 cited
- → DNA Sequence-Specific Recognition by the Saccharomyces cerevisiae “TATA” Binding Protein: Promoter-Dependent Differences in the Thermodynamics and Kinetics of Binding(1998)44 cited
- → Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab(2020)17 cited
- → Characterization and Modeling of Reversible Antibody Self-Association Provide Insights into Behavior, Prediction, and Correction(2021)14 cited
- → Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of action(2021)9 cited
- → Crystal Structure and Characterization of Human Heavy-Chain Only Antibodies Reveals a Novel, Stable Dimeric Structure Similar to Monoclonal Antibodies(2020)5 cited
- → Flexibility of BIV TAR-Tat: Models of Peptide Binding(2002)4 cited
- → Pharmacological and structural characterization of vibostolimab, a novel anti-TIGIT blocking antibody for cancer immunotherapy(2025)2 cited
- → Author Correction: Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of action(2021)